Joe Rogan talks to Dennis McKenna about people who micro-dose psilocybin.
07:22 min
CLEAR ALL
The first randomized controlled trial to compare the illicit psychedelic psilocybin with a conventional selective serotonin reuptake inhibitor (SSRI) antidepressant found that the former improved symptoms of depression just as well on an established metric—and had fewer side effects.
1
A new generation of research into psilocybin could change how we treat numerous mental health conditions.
The mind-altering drug has been shown to help people suffering from anxiety and depression. But how it helps, who it will serve, and who will profit are open questions.
My first encounter with ketamine did not go well.
2
A single dose of psilocybin, a compound found in “magic mushrooms,” provides long-term relief of anxiety and depression in cancer patients, a new study finds.
3
The new research looked at cancer patients who took part in a study nearly five years ago.
Through this treatment plan, the patient was able to “reconceptualize her trauma” and “was able to move through difficult memories and emotions rather than letting them consume her,” explained U of O associate professor, Monnica Williams.
Two studies used psilocybin to see if the drug could reduce depression and anxiety in cancer patients. The results were striking.
The authors found that micro-dosers tend to harbor less dysfunctional attitudes, exhibit less negative emotionality, and score higher on measures of wisdom, open-mindedness, and creativity.
Amazonian healing traditions collide with Western medical sensibilities.